Compare Citius Pharmaceuticals Inc (CTXR) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Victoria's Secret & Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Victoria's Secret & Co trades at $93.87 (market cap $7.48B). The key difference: Victoria's Secret & Co is far larger — about 373.8× Citius Pharmaceuticals Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VSXY | |
|---|---|---|
Market Cap | $20.01M | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $99.97 |
52-Week Low | $0.48 | $21.34 |
Enterprise Value | $16.23M | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
VSXY trades at $94.6, down 5.37% today but near its 52-week high, with a bullish technical signal and strong support at $93. The company reported Q1 2026 EPS of $0.60, beating expectations, and shows improving net income margins. Analyst consensus is a Buy with a $91 target, while recent news highlights growth through data-driven marketing and international expansion.
Outlook is positive with earnings momentum and international growth, but risks include high valuation (P/E 37.51) and competitive pressures. Investors may find opportunity in continued execution, though margin sustainability and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
